Sweden · Delayed Price · Currency is SEK OncoZenge AB Statistics
Total Valuation
OncoZenge AB has a market cap or net worth of SEK 99.18 million. The enterprise value is 105.74 million.
| Market Cap | 99.18M |
| Enterprise Value | 105.74M |
Important Dates
The next confirmed earnings date is Thursday, September 3, 2026.
| Earnings Date | Sep 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoZenge AB has 14.05 million shares outstanding. The number of shares has increased by 6.89% in one year.
| Current Share Class | 14.05M |
| Shares Outstanding | 14.05M |
| Shares Change (YoY) | +6.89% |
| Shares Change (QoQ) | +4.92% |
| Owned by Insiders (%) | 39.07% |
| Owned by Institutions (%) | 13.53% |
| Float | 4.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,396.89 |
| PB Ratio | 277.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 20.95.
| Current Ratio | 1.26 |
| Quick Ratio | 0.69 |
| Debt / Equity | 20.95 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.36 |
Financial Efficiency
Return on equity (ROE) is -446.60% and return on invested capital (ROIC) is -158.48%.
| Return on Equity (ROE) | -446.60% |
| Return on Assets (ROA) | -120.16% |
| Return on Invested Capital (ROIC) | -158.48% |
| Return on Capital Employed (ROCE) | -288.02% |
| Weighted Average Cost of Capital (WACC) | 11.25% |
| Revenue Per Employee | 71,000 |
| Profits Per Employee | -23.12M |
| Employee Count | 1 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.68% in the last 52 weeks. The beta is 1.35, so OncoZenge AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | +20.68% |
| 50-Day Moving Average | 6.33 |
| 200-Day Moving Average | 6.02 |
| Relative Strength Index (RSI) | 57.59 |
| Average Volume (20 Days) | 65,351 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoZenge AB had revenue of SEK 71,000 and -23.12 million in losses. Loss per share was -1.85.
| Revenue | 71,000 |
| Gross Profit | 71,000 |
| Operating Income | -22.63M |
| Pretax Income | -23.12M |
| Net Income | -23.12M |
| EBITDA | n/a |
| EBIT | -22.63M |
| Loss Per Share | -1.85 |
Balance Sheet
The company has 935,000 in cash and 7.50 million in debt, with a net cash position of -6.57 million or -0.47 per share.
| Cash & Cash Equivalents | 935,000 |
| Total Debt | 7.50M |
| Net Cash | -6.57M |
| Net Cash Per Share | -0.47 |
| Equity (Book Value) | 358,000 |
| Book Value Per Share | 0.03 |
| Working Capital | 1.01M |
Cash Flow
| Operating Cash Flow | -21.34M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 7.50M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -31,877.46% |
| Pretax Margin | -32,557.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoZenge AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.89% |
| Shareholder Yield | -6.89% |
| Earnings Yield | -23.31% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OncoZenge AB has an Altman Z-Score of -14.11 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.11 |
| Piotroski F-Score | 1 |